EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Clinical trial NCT03612739 · WITHDRAWN
Trial details
- NCT number
- NCT03612739
- Sponsor
- Celyad Oncology SA
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-01
- Primary completion
- 2019-05-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.